Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival

Our plain-English summary of Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival, by L. Zhang, M. Huang (MedComm, 2025).

The study

• Authors: L. Zhang, M. Huang
• Journal: MedComm
• Published: 2025;6(9):e70327
• Type of article: Review
• Cited by: 4 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Pleural mesothelioma (PM) presents significant challenges in clinical management, with current treatment options such as chemotherapy, anti-angiogenic therapies, and immunotherapies only modestly extending progression-free survival (PFS) and overall survival (OS). Another relevant reason is the absence of subsequent-line therapy strategies following progression of PM after approved therapy. Despite extensive research efforts, the development of effective targeted therapies has proven difficult, as most identified mutations in PM tend to be tumor suppressors rather than the driving mutations seen in other cancers. This review aims to provide an in-depth analysis of the biological mechanisms of PM, focusing on genetic alterations, the tumor's immune microenvironment, and dysregulated signaling pathways that contribute to tumorigenesis and resistance to treatment. Additionally, we discuss the growing importance of biomarkers for patient stratification and the development of personalized therapeutic approaches tailored to individual molecular profiles. We also explore promising avenues for novel therapeutic strategies, such as combination therapies and immunotherapeutic interventions. By integrating insights from both basic and clinical research, this review seeks to present a comprehensive framework for understanding PM and advancing its therapeutic management, ultimately aiming to improve patient outcomes through more effective and targeted treatment approaches.

© 2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.

In plain English

This article was a narrative review of published research on pleural mesothelioma. It reported no new patient data and did not describe how the studies it covered were chosen. The authors summarized how the disease is thought to develop, how it is diagnosed and staged, and its treatments: surgery, chemotherapy, anti-angiogenic drugs, immunotherapy, and experimental epigenetic and targeted approaches. They described asbestos exposure as the predominant and most well-established cause, and wrote that current evidence does not support a causal role for simian virus 40. Among the studies the review cited, the CheckMate 743 trial reported a median survival of 18.1 months with nivolumab plus ipilimumab versus 14.1 months with chemotherapy. An Australian real-world study of 119 patients reported a median survival of 14.5 months with first-line treatment. The authors noted that no targeted therapy has been approved for pleural mesothelioma. They concluded that current combined treatments yield only modest survival benefits because of therapeutic resistance and tumor heterogeneity. Several trial figures differ between the article's tables and its text.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review of published basic and clinical research on pleural mesothelioma; no methods for selecting studies are described
• Who was studied: No study population of its own; the review drew on published laboratory and clinical studies of pleural mesothelioma (PM)
• Exposure: Asbestos fibers in general (no fiber type specified) were described as the main cause. The review also discussed simian virus 40 (SV40) and inherited gene mutations (CDKN2A, NF2, BAP1) as factors in disease development.
• Main results:
  • The authors described asbestos exposure as the predominant and best-established cause of pleural mesothelioma.
  • The authors wrote that current evidence does not support SV40 as a cause of pleural mesothelioma.
  • Citing earlier work, the review stated that about 10% of mesothelioma patients carry inherited (germline) mutations in cancer susceptibility genes.
  • Citing the CheckMate 743 trial, the review reported a median survival of 18.1 months with nivolumab plus ipilimumab versus 14.1 months with chemotherapy.
  • Citing the Australian RIOMeso real-world study of 119 patients with pleural mesothelioma, the review reported that 75% received ipilimumab plus nivolumab first, and that median survival for first-line treatment was 14.5 months.
  • Citing CheckMate 743, the review reported severe side effects in 21% of patients on nivolumab plus ipilimumab versus 8% of patients on chemotherapy.
  • The authors judged that pleurectomy/decortication (P/D) appears superior to extrapleural pneumonectomy (EPP) for surgery.
  • The authors stated that no targeted therapy has been approved for pleural mesothelioma.
• The authors' conclusion: The authors concluded that current combinations of chemotherapy, anti-angiogenic agents and immunotherapy give only modest survival benefits, because of therapeutic resistance and tumor heterogeneity.
• Limitations the authors state:
  • About the evidence they reviewed, the authors noted that clinical trials enroll strictly selected patients, whose results may not match real-world outcomes.
  • The authors stated that the existing data on immune checkpoint inhibitors are insufficient and that more real-world evidence is needed.

Topics

Medical terms in this study, explained in our Lexicon: Pleural Mesothelioma, Prognosis, Chemotherapy, Progression-Free Survival, Overall Survival, Carcinogenesis, Biomarker.

Related studies

• The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment — V. Galani, A. Varouktsi, et al. (2019)
• The Role of Epithelial-Mesenchymal Transition in Malignant Pleural Mesothelioma: From Pathogenesis to Diagnosis and Treatment — D.E. Magouliotis, F. Minervini, et al. (2025)
• Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma — W. Zhang, X. Wu, et al. (2015)
• Improvement of Malignant Pleural Mesothelioma Prognosis: Early Diagnosis and Multimodality Treatment — C.J. Ban, H.Z. Shi, et al. (2017)
• Malignant Peritoneal Mesothelioma: An In-Depth and Up-to-Date Review of Pathogenesis, Diagnosis, Management and Future Directions — J.B. Karpes, R. Shamavonian, et al. (2023)
• Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies — R.K. Sahu, S. Ruhi, et al. (2023)

Browse return to medical research.